What Aktis Oncology Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 9 |
| Sells | 2 | 11 |
| Total trades | 3 | 43 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 12,500 | 10,791,551 |
| Disposed | 12,500 | 120,421 |
| Net activity | +0 | +10,671,130 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Czibere Akos | Chief Medical Officer | Sep 23 | Disclosed 10b5-1 sale · S | −7,401 | $21.03 | −$156K | 0 |
| Czibere Akos | Chief Medical Officer | Sep 23 | Disclosed 10b5-1 sale · S | −5,099 | $20.19 | −$103K | 7,401 |
| Czibere Akos | Chief Medical Officer | Sep 23 | Exercise / conversion · M | +12,500 | $4.95 | +$61.9K | 12,500 |
| Herrmann Ken | Director | Jul 20 | Open-market sale · S | −1,350 | $24.56 | −$33.2K | 0 |
| Herrmann Ken | Director | Jul 20 | Open-market sale · S | −3,506 | $24.56 | −$86.1K | 1,350 |
| Herrmann Ken | Director | Jul 20 | Exercise / conversion · M | +1,350 | $1.91 | +$2.58K | 4,856 |
| Herrmann Ken | Director | Jul 20 | Exercise / conversion · M | +3,506 | $0.08 | +$280 | 3,506 |
| Herrmann Ken | Director | Jul 17 | Open-market sale · S | −3,065 | $25.21 | −$77.3K | 0 |
| Herrmann Ken | Director | Jul 17 | Exercise / conversion · M | +3,065 | $0.08 | +$245 | 3,065 |
| Czibere Akos | Chief Medical Officer | Jul 08 | Open-market sale · S | −4,371 | $28.71 | −$125K | 0 |
| Czibere Akos | Chief Medical Officer | Jul 08 | Open-market sale · S | −30,829 | $27.95 | −$862K | 4,371 |
| Czibere Akos | Chief Medical Officer | Jul 08 | Open-market sale · S | −14,800 | $27.13 | −$401K | 35,200 |
| Czibere Akos | Chief Medical Officer | Jul 08 | Exercise / conversion · M | +50,000 | $4.95 | +$248K | 50,000 |
| Ron-Bigger Shulamit | Chief Operating Officer | Jul 08 | Open-market sale · S | −4,200 | $28.75 | −$121K | 0 |
| Ron-Bigger Shulamit | Chief Operating Officer | Jul 08 | Open-market sale · S | −30,000 | $27.94 | −$838K | 4,200 |
| Ron-Bigger Shulamit | Chief Operating Officer | Jul 08 | Open-market sale · S | −15,800 | $27.13 | −$429K | 34,200 |
| Ron-Bigger Shulamit | Chief Operating Officer | Jul 08 | Exercise / conversion · M | +50,000 | $3.66 | +$183K | 50,000 |
| EcoR1 Capital, Llc | Director | Jan 12 | Open-market buy · P | +144,443 | $18.00 | +$2.6M | 347,305 |
| EcoR1 Capital, Llc | Director | Jan 12 | Open-market buy · P | +2,077,779 | $18.00 | +$37.4M | 4,348,658 |
| EcoR1 Capital, Llc | Director | Jan 12 | Derivative Conversion · C | +128,506 | — | — | 128,506 |
Loading...